Estimation of Early Graft Function Using the BETA-2 Score Following Clinical Islet Transplantation

Transpl Int. 2022 Jul 6:35:10335. doi: 10.3389/ti.2022.10335. eCollection 2022.

Abstract

Little is known about how early islet graft function evolves in the clinical setting. The BETA-2 score is a validated index of islet function that can be calculated from a single blood sample and lends itself to frequent monitoring of graft function. In this study, we characterized early graft function by calculating weekly BETA-2 score in recipients who achieved insulin independence after single transplant (group 1, n = 8) compared to recipients who required a second transplant before achieving insulin independence (group 2, n = 7). We also determined whether graft function 1-week post-transplant was associated with insulin independence in individuals who received initial transplant between 2000-2017 (n = 125). Our results show that graft function increased rapidly reaching a plateau 4-6 weeks post-transplant. The BETA-2 score was higher in group 1 compared to group 2 as early as 1-week post-transplant (15 + 3 vs. 9 + 2, p = 0.001). In an unselected cohort, BETA-2 at 1-week post-transplant was associated with graft survival as defined by insulin independence during median follow up of 12 months (range 2-119 months) with greater survival among those with BETA-2 score >10 (p < 0.001, log-rank test). These findings suggest that primary graft function is established within 4-6 weeks post-transplant and graft function at 1-week post-transplant predicts long-term transplant outcomes.

Keywords: BETA-2 score; engraftment; graft function; graft survival; islet transplantation.

MeSH terms

  • Blood Glucose
  • C-Peptide
  • Diabetes Mellitus, Type 1* / surgery
  • Graft Survival
  • Humans
  • Insulin / therapeutic use
  • Islets of Langerhans Transplantation* / methods

Substances

  • Blood Glucose
  • C-Peptide
  • Insulin